AstraZeneca plc is developing tesaglitazar, an oral dual peroxisome proliferator-activated receptor alpha/gamma agonist, for the potential improvement of dyslipidemia and glycemic control in type 2 diabetic patients.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
tesaglitazar astrazeneca
4
astrazeneca plc
4
plc developing
4
developing tesaglitazar
4
tesaglitazar oral
4
oral dual
4
dual peroxisome
4
peroxisome proliferator-activated
4
proliferator-activated receptor
4
receptor alpha/gamma
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!